Has Marcos Valdez received payments from drug or device companies?

Yes. Drug and device makers reported $31,767 in general payments to Marcos Valdez across 267 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marcos Valdez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marcos Valdez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marcos Valdez

Neurology with Special Qualifications in Child Neurology · Corpus Christi, TXNPI 1104800200

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Neurelis, Inc. at 51.0% of the total. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,767in general payments, 2019–2025

Across 267 payments — averaging $118.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurelis, Inc.$16K
Otter Pharmaceuticals, LLC$5K
Supernus Pharmaceuticals, Inc.$3K
Biogen$2K
Ironshore Pharmaceuticals Inc.$546
AstraZeneca$469
plus $5K from 41 others

$165,350in research payments, 2019–2025

Across 24 payments — averaging $6889.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$165K

What the payments were for

Consulting fees$6,20720%
Speaking & faculty fees$13,08141%
Travel & lodging$1,8186%
Food & beverage$9,74331%
Education$9183%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurelis, Inc.	31	$16,193
Otter Pharmaceuticals, LLC	13	$4,514
Supernus Pharmaceuticals, Inc.	81	$3,073
Biogen	26	$1,606
Ironshore Pharmaceuticals Inc.	9	$546
AstraZeneca	5	$469
Biomarin Pharmaceutical Inc.	6	$365
Travere Therapeutics, Inc.	3	$345
UCB, Inc.	4	$243
Regeneron Healthcare Solutions, Inc.	2	$241
GSK	3	$237
Jazz Pharmaceuticals Inc.	4	$232
Immedica Pharma US, Inc.	5	$225
Pharming Healthcare, Inc.	2	$224
Sanofi	2	$220
Biomerieux Inc	2	$206
Greenwich Biosciences, Inc.	2	$185
Ultragenyx Pharmaceutical Inc.	2	$185
Phadia US Inc.	2	$165
Livanova USA, Inc.	6	$165
Acadia Pharmaceuticals Inc	4	$146
Collegium Pharmaceutical, Inc.	2	$145
Sumitomo Pharma America, Inc.	13	$132
PTC Therapeutics, Inc.	2	$131
LNHC, Inc	1	$125
Ipsen Biopharmaceuticals, Inc	1	$125
Sunovion Pharmaceuticals Inc.	6	$119
Rhythm Pharmaceuticals, Inc.	1	$112
Teva Pharmaceuticals USA, Inc.	1	$105
Kyowa Kirin, Inc.	1	$100
Shire North American Group Inc	1	$97
Biofire Diagnostics, LLC	1	$90
Mirum Pharmaceuticals, Inc.	1	$86
Biocodex, Inc.	3	$81
Zogenix Inc.	3	$77
Genentech, Inc.	1	$73
ITF Therapeutics LLC	2	$64
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	2	$58
Takeda Pharmaceuticals U.S.A., Inc.	1	$51
Sarepta Therapeutics, Inc.	2	$48
Catalyst Pharmaceuticals, Inc.	1	$30
Aquestive Therapeutics, Inc.	2	$29
Advanced Respiratory, Inc	1	$27
SK Life Science, Inc.	1	$23
Genentech USA, Inc.	1	$21
Nobelpharma America, LLC	1	$17
Otsuka America Pharmaceutical, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VALTOCO$15,626
SYMPAZAN$4,266
OXTELLAR XR$1,850
DUPIXENT$241
(815) Thiola$240
Jornay PM 20mg capsules (Bottle of 100)$233
JOENJA$224
Palynziq$176
Epidiolex$160
XYWAV$135
ZTALMY$134
Bylvay$125
ZELSUVMI$125
JORNAY PM$125
Nayzilam$122
KOSELUGO$122
BENLYSTA$121
BIOFIRE SPOTFIRE Respiratory (R) Panel$121
QELBREE$110
EMFLAZA$106

How this compares

$31,767 in reported general payments places this provider in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.

See all neurology with special qualifications in child neurology providers in Texas →

Other neurology with special qualifications in child neurology in Corpus Christi

Carol DelineCorpus Christi$4K
Roy EltermanDallas$5.9M
Huda ZoghbiHouston$5.5M
Diana CastroDenton$343K
Shade MoodyHouston$194K
Mary Kay KoenigHouston$171K
Michael PerryFort Worth$162K
Raphael SchiffmannDallas$88K
Mauricio Delgado-AyalaDallas$75K
Kaitlin BatleyDallas$74K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →